ANTI
BODIES
CON
NECT

Antibody magazine
  • Letter to the Shareholders

    The year 2012 was one of the most successful in the history of MorphoSys. MorphoSys sharpened its focus on therapeutic applications and made clear progress in respect of its future technologies and products.

    Letter to the Shareholders
  • Financial Results

    In 2012, MorphoSys was again able to invest significantly in research and development. Financial stability, based on cash and cash equivalents of currently more than €180 million together with a cash-generating partner business continues to be one of the greatest strengths of our company.

    Financial Results
  • Product Pipeline

    Major advances in the development of several programs in our clinical pipeline were the decisive events of the year. Our long-term strategy of using innovative technology to engineer the medicines of tomorrow is paying off as momentum builds in the pipeline.

    Product Pipeline

Preview

  1. MOR103

    Multiple sclerosis

    MOR103
  2. Dr. Simon E. Moroney

    Interview

    Interview
  3. Our technology platforms

    Ylanthia – 100 billion high potentials

    Our technology platforms
  4. Antibodies – Basics

    Antibodies – The Immune System’s Defense Team

    Antibodies – Basics
  5. Jens Holstein

    Interview

    Interview
  6. Dr. Arndt Schottelius

    Interview

    Interview
  7. Our technology platforms

    Slonomics – DNA Engineering to Construct Proteins

    Our technology platforms
  8. Dr. Marlies Sproll

    Interview

    Interview
  9. MOR208

    Chronic lymphocytic leukemia

    MOR208
  10. Antibodies – Basics

    Antibody Structure and Therapeutic Applications

    Antibodies – Basics
  11. MOR202

    Multiple myeloma

    MOR202
  12. MOR103

    Rheumatoid arthritis

    MOR103